N-methyl-3-piperidyl benzilate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 62495 |
| CHEMBL ID | 139948 |
| SCHEMBL ID | 1739564 |
| MeSH ID | M0042384 |
| Synonym |
|---|
| benzilic acid, 1-methyl-3-piperidyl ester |
| benzeneacetic acid, .alpha.-hydroxy-.alpha.-phenyl-, 1-methyl-3-piperidinyl ester |
| 1-methyl-3-piperidyl benzilate |
| brn 0299160 |
| jb 336 |
| benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 1-methyl-3-piperidinyl ester |
| einecs 222-033-1 |
| dea no. 7484 |
| alpha-hydroxy-alpha-phenylbenzeneacetic acid, 1-methyl-3-piperidinyl ester |
| n-methyl-3-piperidyl benzilate |
| NCGC00160607-01 |
| CHEMBL139948 , |
| (1-methylpiperidin-3-yl) 2-hydroxy-2,2-diphenylacetate |
| dtxsid2046258 , |
| dtxcid0026258 |
| tox21_111933 |
| cas-3321-80-0 |
| AKOS024327589 |
| 4-21-00-00021 (beilstein handbook reference) |
| unii-3a5hm769qx |
| 3321-80-0 |
| 3a5hm769qx , |
| .alpha.-hydroxy-.alpha.-phenylbenzeneacetic acid, 1-methyl-3- piperidinyl ester |
| benzeneacetic acid, .alpha.-hydroxy-.alpha.-phenyl-, 1-methyl-3- piperidinyl ester |
| 3-piperidinol, 1-methyl-, benzilate (ester) |
| n-methyl-3-hydroxypiperidine benzilate |
| SCHEMBL1739564 |
| alpha-hydroxy-alpha-phenyl-benzeneacetic acid 1-methyl-3-piperidinyl ester |
| 1-methyl-3-piperidyl benzylate |
| ZBEILXWHVSVDBN-UHFFFAOYSA-N |
| 1-methyl-3-piperidinyl hydroxy(diphenyl)acetate # |
| bdbm50473047 |
| (1-methyl-3-piperidyl) 2-hydroxy-2,2-diphenyl-acetate |
| Q15409361 |
| 1-methyl-3-piperidylbenzilate |
| PD014275 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 15.8489 | 0.0054 | 28.0263 | 1,258.9301 | AID1346985 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 16.7855 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 10.0000 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 2.6603 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 0.0011 | 0.0001 | 0.5797 | 10.0000 | AID142341 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 0.0011 | 0.0001 | 1.4833 | 9.1400 | AID142341 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 0.0011 | 0.0001 | 0.6868 | 8.2600 | AID142341 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | Ki | 0.0011 | 0.0001 | 0.6661 | 8.2600 | AID142341 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 0.0011 | 0.0001 | 0.5890 | 8.2600 | AID142341 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID24405 | Partition coefficient (logP) | 2000 | Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23 | Synthesis, (18)F-labeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors. |
| AID142341 | Tested in vitro for binding affinity against Muscarinic acetylcholine receptor from rat brain using [3H]- Scopolamine as radioligand | 2000 | Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23 | Synthesis, (18)F-labeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||